Patents by Inventor Craig K. Esser

Craig K. Esser has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted N-carboxyalkylpeptidyl derivatives as antidegenerative agents
    Patent number: 6090785
    Abstract: Novel N-carboxyalkylpeptidyl compounds represented by the formula ##STR1## which are found to be useful inhibitors of matrix metalloendoproteinases which degrade major components of articular cartilage and basement membranes causing degenerative diseases such as arthritis, periodontal disease, corneal ulceration and the like, and certain cancers, are described.
    Type: Grant
    Filed: October 15, 1992
    Date of Patent: July 18, 2000
    Assignee: Merck & Co., Inc.
    Inventors: Philippe L. Durette, Craig K. Esser, William K. Hagmann, Ihor E. Kopka
  • Substituted N-carboxyalkylpeptidyl derivatives as antidegenerative active agents
    Patent number: 5932551
    Abstract: Novel N-carboxyalkylpeptidyl compounds of formula I are found to be useful inhibitors of matrix metalloendoproteinase-mediated diseases including osteoarthritis, rheumatoid arthritis, septic arthritis, tumor invasion in certain cancers, periodontal disease, corneal ulceration, proteinuria, dystrophobic epidermolysis bullosa, and coronary thrombosis associated with atherosclerotic plaque rupture. The matrix metalloendoproteinases are a family of zinc-containing proteinases including but not limited to stromelysin, collagenase, and gelatinase, that are capable of degrading the major components of articular cartilage and basement membranes. The inhibitors claimed herein may also be useful in preventing the pathological sequelae following a traumatic injury that could lead to a permanent disability. These compounds may also have utility as a means for birth control by preventing ovulation or implantation.
    Type: Grant
    Filed: May 1, 1997
    Date of Patent: August 3, 1999
    Assignee: Merck & Co., Inc.
    Inventors: Charles G. Caldwell, Kevin T. Chapman, Craig K. Esser, William K. Hagmann, Ihor E. Kopka, Scott A. Polo, Soumya P. Sahoo, Philippe L. Durette
  • Substituted 4-aza-5.alpha.-androstan-ones as 5.alpha.-reductase inhibitors
    Patent number: 5693809
    Abstract: Described are new 16-substituted and 7,16-disubstituted 4-aza-5.alpha.-androstan-3-ones and related compounds as 5.alpha.-reductase inhibitors.
    Type: Grant
    Filed: May 12, 1995
    Date of Patent: December 2, 1997
    Assignee: Merck & Co., Inc.
    Inventors: Philippe L. Durette, William Hagmann, Gary H. Rasmusson, Richard L. Tolman, Ihor E. Kopka, Soumya P. Sahoo, Craig K. Esser, Nathan G. Steinberg, Donald W. Graham, Bruce E. Witzel
  • 15-substituted 4-azasteroids
    Patent number: 5359071
    Abstract: Compounds of the formula ##STR1## or a pharmaceutically acceptable salt or ester thereof, wherein R.sup.1 is selected from the group consisting of hydrogen and C.sub.1-10 alkyl;R.sup.2 is selected from the group consisting of hydrogen and C.sub.1-10 alkyl;R.sup.3 is selected from the group consisting of C.sub.1-10 alkoxyl, C.sub.1-10 alkyl and cyano;R.sup.4 is selected from the group consisting of C.sub.1-10 alkenyloxyl, C.sub.1-10 alkoxyl, C.sub.1-10 alkyl, C.sub.1-10 alkylcarbamic, C.sub.1-10 alkylcarbonyloxyl, carbonyl, hydroxyl, and --NHR.sup.5, andR.sup.5 is selected from the group consisting of hydrogen and C.sub.1-10 alkylcarbonyl. Such compounds are useful as selective antagonists of testosterone 5.alpha.-reductase 1.
    Type: Grant
    Filed: March 12, 1993
    Date of Patent: October 25, 1994
    Assignee: Merck & Co., Inc.
    Inventors: Philippe L. Durette, Craig K. Esser, William Hagmann, Ihor E. Kopka